Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-akt | 7 | 2021 | 60 | 1.430 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2022 | 86 | 1.340 |
Why?
|
| Imidazoles | 7 | 2019 | 62 | 0.940 |
Why?
|
| Piperazines | 7 | 2019 | 84 | 0.920 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2020 | 17 | 0.790 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 17 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 4 | 2019 | 34 | 0.600 |
Why?
|
| Cisplatin | 6 | 2022 | 60 | 0.560 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2022 | 68 | 0.530 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 6 | 0.500 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 10 | 0.500 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 198 | 0.500 |
Why?
|
| Cell Line, Tumor | 12 | 2022 | 253 | 0.490 |
Why?
|
| DNA Methylation | 1 | 2016 | 157 | 0.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 236 | 0.450 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 110 | 0.440 |
Why?
|
| Models, Biological | 1 | 2016 | 318 | 0.430 |
Why?
|
| Autophagy | 4 | 2021 | 31 | 0.400 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 64 | 0.370 |
Why?
|
| Apoptosis | 8 | 2019 | 209 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 117 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 402 | 0.280 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 543 | 0.270 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 9 | 0.240 |
Why?
|
| Neoplasms | 2 | 2018 | 230 | 0.240 |
Why?
|
| Tamoxifen | 2 | 2022 | 30 | 0.230 |
Why?
|
| Animals | 3 | 2022 | 3503 | 0.200 |
Why?
|
| Osteosarcoma | 3 | 2018 | 40 | 0.200 |
Why?
|
| Glycolysis | 3 | 2018 | 13 | 0.200 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2022 | 3 | 0.190 |
Why?
|
| Humans | 16 | 2022 | 25967 | 0.190 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 128 | 0.180 |
Why?
|
| Fatty Acids | 1 | 2021 | 38 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 206 | 0.180 |
Why?
|
| Mice, Nude | 1 | 2020 | 25 | 0.170 |
Why?
|
| Transfection | 1 | 2020 | 121 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2018 | 11 | 0.160 |
Why?
|
| Mice | 2 | 2022 | 1352 | 0.160 |
Why?
|
| Carboxypeptidases | 2 | 2022 | 8 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 46 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 10 | 0.150 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2018 | 3 | 0.150 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 3 | 0.150 |
Why?
|
| Sp1 Transcription Factor | 1 | 2018 | 5 | 0.150 |
Why?
|
| Adenosine | 1 | 2018 | 8 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 19 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 577 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 55 | 0.140 |
Why?
|
| Cell Lineage | 1 | 2015 | 25 | 0.120 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 79 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 15 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.110 |
Why?
|
| Staurosporine | 1 | 2013 | 2 | 0.100 |
Why?
|
| G2 Phase | 1 | 2013 | 5 | 0.100 |
Why?
|
| G1 Phase | 1 | 2013 | 16 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2022 | 50 | 0.100 |
Why?
|
| Methylation | 2 | 2019 | 10 | 0.080 |
Why?
|
| Histones | 2 | 2019 | 31 | 0.080 |
Why?
|
| MCF-7 Cells | 2 | 2021 | 15 | 0.080 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 7 | 0.070 |
Why?
|
| Cell Survival | 2 | 2019 | 116 | 0.070 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2019 | 7 | 0.070 |
Why?
|
| RNA Interference | 2 | 2019 | 37 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2021 | 437 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 43 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 14 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 143 | 0.060 |
Why?
|
| Male | 1 | 2020 | 14277 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2014 | 118 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 28 | 0.050 |
Why?
|
| Histone Demethylases | 1 | 2022 | 3 | 0.050 |
Why?
|
| Lysine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cadherins | 1 | 2022 | 30 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 16 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2022 | 50 | 0.050 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 3 | 0.050 |
Why?
|
| Aurora Kinase A | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 19 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 64 | 0.050 |
Why?
|
| Autophagy-Related Proteins | 1 | 2019 | 4 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 5 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 11 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 3 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 39 | 0.030 |
Why?
|
| Pyrazines | 1 | 2017 | 12 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Macrolides | 1 | 2015 | 6 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Superoxides | 1 | 2015 | 24 | 0.030 |
Why?
|
| Chloroquine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2015 | 17 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 26 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 61 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 88 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 106 | 0.030 |
Why?
|
| Oxygen | 1 | 2015 | 63 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 51 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 105 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cyclin B | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2013 | 5 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
| Tetraploidy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cyclin A | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Female | 1 | 2021 | 14734 | 0.010 |
Why?
|